Neurology News

Following a hybrid conference last year, PAINWeek 2022 will be back in full swing, as this year’s meeting will be fully in-person.

The 2022 PAINWeek and BRAINWeek conferences, Sept. 6-9 and Sept. 28-30 in Las Vegas, will feature migraine tracks presented by the world-renowned Diamond Headache Clinic.

The American Society of Interventional Pain Physicians and the Interventional Pain Management Tracks will return to the PAINWeek National Conference, taking place Sept. 6-9 in Las Vegas.

Amneal Pharmaceuticals Inc. announced it has submitted a new drug application to the FDA for IPX203, an oral formulation of carbidopa/levodopa extended-release capsules for the treatment of Parkinson’s disease.

This year’s PAINWeek conference, Sept. 6-9 in Las Vegas, will feature more than 75 credit hours of pain management tracks, including the Advanced Practice Provider Track, featuring diverse faculty with expertise in pain management.

In this edition, BMI is associated with dementia in women and linked with disease in men; Healthy diet, physical activity are linked to lower mortality in adults with PD; mild TBI and CT scans and more.

Rafa Laboratories announced the FDA has granted approval for its 10 mg midazolam autoinjector to treat status epilepticus in adults.

Canadian-based Neurolytixs Inc. announced it has secured a United States patent for technology that can identify mild traumatic brain injuries more accurately and rapidly, particularly in young athletes with concussions.

Vamorolone demonstrated efficacy and safety in the treatment of boys with Duchenne muscular dystrophy over a 24-week treatment period and may be safer than prednisone, according to a study published in JAMA Neurology.

Digital therapeutics company Theranica announced it has received $45 million in investor funding, which the company will use to finance commercial expansion of its prescription migraine treatment device, Nerivio.